Business WireMerck Expands Colorectal Cancer Portfolio Through License Agreement with Inspirna First-in-class ompenaclide (RGX-202) is currently in Phase II development for RAS-mutated advanced or metastatic colorectal cancer. .17 hours ago
Business WireMerck Expands Colorectal Cancer Portfolio Through License Agreement with Inspirna First-in-class ompenaclide (RGX-202) is currently in Phase II development for RAS-mutated advanced or metastatic colorectal cancer. .17 hours ago
Your article helped me a lot, is there any more related content? Thanks!
Your article helped me a lot, is there any more related content? Thanks!
I don’t think the title of your article matches the content lol. Just kidding, mainly because I had some doubts after reading the article.